Kaizen Advisory’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
Kaizen Advisory's BMY Position: Q4 2018 in Review
Kaizen Advisory increased its Bristol-Myers Squibb (BMY) stake by 18% in Q4 2018, buying an estimated $35.6K and bringing the position to 4,430 shares worth $230K. The position accounts for 0.16% of the portfolio, ranked #152.
Kaizen Advisory first reported a position in BMY in Q4 2017 and has held it in 5 quarters since. The position peaked at $1.21M in Q4 2017. 1,765 funds tracked by Wall St. Rank hold BMY as of Q4 2018.
- Kaizen Advisory held 4,430 shares of Bristol-Myers Squibb worth $230K as of Q4 2018.
- Kaizen Advisory bought 662 Bristol-Myers Squibb shares in Q4 2018, an estimated $35.6K.
- Bristol-Myers Squibb made up 0.16% of Kaizen Advisory's portfolio in Q4 2018, its #152 holding.
- Kaizen Advisory first reported a position in Bristol-Myers Squibb in Q4 2017 and has held it in 5 quarters since.
- Kaizen Advisory's Bristol-Myers Squibb position peaked at $1.21M in Q4 2017.
- 1,765 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2018.
Based on Kaizen Advisory's 13F filing for Q4 2018, filed 15 Feb 2019.